

(Note) This document has been translated from the Japanese original for reference purposes only. In the event of any discrepancy between this translated document and the Japanese original, the original shall prevail.

October 1, 2025

Company Name: Tokuyama Corporation

Representative Name: Hiroshi Yokota,

Representative Director, President and Executive Officer

(Code No. 4043, Prime Market, TSE)

Contact: Tetsuya Nakano, General Manager

Corporate Communications & Investor Relations Dept.

TEL: +81-3-5207-2552

(Update of the Previous Announcement)
Notice Concerning the Acquisition of a Newly Established Company
that will succeed JSR's in vitro diagnostic pharmaceutical business

Tokuyama Corporation (hereinafter “Tokuyama,” “the Company,” or “we”) having resolved at the Board of Directors’ meeting held on April 22, 2025, to acquire the in vitro diagnostics and in vitro diagnostic pharmaceutical materials businesses (hereinafter “the Target Businesses”) held by JSR Corporation (hereinafter “JSR”)—as disclosed in the “Notice Concerning the Acquisition of a Newly Established Company that will succeed JSR’s in vitro diagnostic pharmaceutical business” dated April 22, 2025—executed a Share Transfer Agreement (hereinafter “the Agreement”) on the same day.

Under the Agreement, JSR will transfer the Target Businesses to JSR-01 Corporation (hereinafter “the Newly Established Company”), a new company established by JSR, through a company split (absorption-type split). On October 1, 2025, the Company completed acquisition procedures for all shares of the Newly Established Company. The Company would also like to take this opportunity to announce that, in connection with its acquisition as a subsidiary, the Newly Established Company will have a different name, location, and representative, effective from the same date.

Details of the absorption-type company split and share acquisition are as set forth in the “Notice Concerning the Acquisition of a Newly Established Company that will succeed JSR’s in vitro diagnostic pharmaceutical business,” dated April 22, 2025.

1. Outline of the Subsidiary to be Transferred

(1) Name	<u>Tokuyama Life Science Corporation</u> (Splitting company in absorption-type split)	
(2) Location	<u>SUMITOMO FUDOSAN SHIBADAIMON NICHOME BLDG.</u> <u>2-11-8 Shibadaimon, Minato-ku, Tokyo, Japan</u>	
(3) Name and Title of Representative	<u>Tomohiro Inoue, Representative Director and President</u>	
(4) Business	In vitro diagnostics business, in vitro diagnostic materials business and stock management business	
(5) Capital	1 million yen	
(6) Date of Establishment	<u>June 9, 2025</u>	
(7) Major Shareholder and Ratio of Shareholding	<u>Tokuyama Corporation</u>	100%

(8) Relationship between the Listed Company and the Company Concerned	Capital Relationship	<u>The subsidiary is wholly owned by the Company.</u>
	Personnel Relationship	<u>A director of the Company also serves as a director of the subsidiary.</u>
	Transaction Relationship	<u>Tokuyama plans to provide loans to the subsidiary for its business.</u>

(Note1) With the establishment of a new company, details regarding the newly established company's financial position and business results for the most recent fiscal year have not been finalized.

2. Changes in Company Name, Location, and Representative

(1) Change in Company Name

	After the change	Before the change
Company Name	Tokuyama Life Science Corporation	JSR-01 Corporation

(2) Change in Location

	After the change	Before the change
Location	SUMITOMO FUDOSAN SHIBADAIMON NICHOME BLDG. 2-11-8 Shibadaimon, Minato-ku, Tokyo, Japan	1-9-2, Higashi-Shimbashi, Minato-ku, Tokyo, Japan

(3) Change in Representative

	After the change	Before the change
Name and Title of Representative	Tomohiro Inoue, Representative Director and President	Director, Hiroki Ito

(4) Reason for the Change in the Company Name

Following the acquisition of a subsidiary through a stock acquisition, to clarify its position within the Tokuyama Group.

(5) Date of Changes

October 1, 2025

3. Impact on Business Performance

Any impact of the acquisition of shares on Tokuyama's consolidated financial results for the fiscal year ending March 31, 2026, is currently being assessed, but the Company will promptly give notice if the event a matter requiring disclosure arises.

(Note) The performance forecast and other forward-looking statements contained in this material have been prepared on the basis of information available at this point and certain assumptions which are judged to be rational, and may be substantially different from the actual performance because of various factors that may arise from now on.